Cite
HARVARD Citation
Johnson, M. et al. (n.d.). 421PPreliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors. Annals of oncology. p. . [Online].